Compare Amphastar Pharmaceuticals Inc (AMPH) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Jumia Technologies AG - ADR — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Jumia Technologies AG - ADR trades at $6.88 (market cap $868.21M). The key difference: Amphastar Pharmaceuticals Inc and Jumia Technologies AG - ADR are close in size by market cap. Which is the better fit depends on your goals.
| AMPH | JMIA | |
|---|---|---|
Market Cap | $826.08M | $868.21M |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $14.60 |
52-Week Low | $16.87 | $4.26 |
Enterprise Value | $1.22B | $815.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
JMIA trades at $7.01, up 1.45% today, amid a bearish technical signal and mixed earnings. The company reported Q1 2026 revenue growth of 39% but missed EPS expectations, with a net income margin of -30.79%. Cash flow improved with a net inflow of $21.31M in 2025, and management reaffirmed a 2027 profitability target. The stock shows neutral oscillators but bearish moving averages, with support and resistance clustered around $7.
The outlook hinges on JMIA's path to profitability by 2027, supported by expansion initiatives and partnerships like Starlink. Risks include persistent losses, competitive pressures in African e-commerce, and macroeconomic headwinds. Analyst consensus is strongly bullish with 71% buy ratings, but investors must weigh growth potential against execution risks and current negative returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
